{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T23:07:51Z","timestamp":1794092871623,"version":"4.8.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.sapharm.2021.05.007","type":"journal-article","created":{"date-parts":[[2021,5,15]],"date-time":"2021-05-15T07:07:07Z","timestamp":1621062427000},"page":"2269-2275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Methods for evaluating the benefit and harms of deprescribing in observational research using routinely collected data"],"prefix":"10.1016","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9838-3625","authenticated-orcid":false,"given":"Frank","family":"Moriarty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wade","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3228-0046","authenticated-orcid":false,"given":"Fiona","family":"Boland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.sapharm.2021.05.007_bib1","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1080\/14740338.2018.1546841","article-title":"An update on the clinical consequences of polypharmacy in older adults: a narrative review","volume":"17","author":"Wastesson","year":"2018","journal-title":"Expet Opin Drug Saf"},{"key":"10.1016\/j.sapharm.2021.05.007_bib2","series-title":"Guide to Good Prescribing - A Practical Manual","author":"De Vries","year":"1994"},{"issue":"6","key":"10.1016\/j.sapharm.2021.05.007_bib3","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.sapharm.2018.08.014","article-title":"Deprescribing recommendations: an essential consideration for clinical guideline developers","volume":"15","author":"Moriarty","year":"2019","journal-title":"Res Soc Adm Pharm"},{"key":"10.1016\/j.sapharm.2021.05.007_bib4","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006544","article-title":"Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis","volume":"4","author":"Anderson","year":"2014","journal-title":"BMJ Open"},{"issue":"3","key":"10.1016\/j.sapharm.2021.05.007_bib5","doi-asserted-by":"crossref","DOI":"10.3399\/bjgpopen20X101096","article-title":"Barriers and facilitators to deprescribing in primary care: A systematic review","volume":"4","author":"Doherty","year":"2020","journal-title":"BJGP Open."},{"issue":"3","key":"10.1016\/j.sapharm.2021.05.007_bib6","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/bcp.12975","article-title":"The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis","volume":"82","author":"Page","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"675","key":"10.1016\/j.sapharm.2021.05.007_bib7","doi-asserted-by":"crossref","first-page":"e663","DOI":"10.3399\/bjgp18X699041","article-title":"Effects of discontinuation of chronic medication in primary care: a systematic review of deprescribing trials","volume":"68","author":"Thio","year":"2018","journal-title":"Br J Gen Pract"},{"issue":"3","key":"10.1016\/j.sapharm.2021.05.007_bib8","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/prp2.476","article-title":"Health professionals' and researchers' opinions on conducting clinical deprescribing trials","volume":"7","author":"Clough","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"10.1016\/j.sapharm.2021.05.007_bib9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.archger.2014.03.006","article-title":"Challenges and strategies pertaining to recruitment and retention of frail elderly in research studies: a systematic review","volume":"59","author":"Provencher","year":"2014","journal-title":"Arch Gerontol Geriatr"},{"issue":"10","key":"10.1016\/j.sapharm.2021.05.007_bib10","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1111\/jgs.16697","article-title":"Outcome measures for interventions to reduce inappropriate chronic drugs: a narrative review","volume":"68","author":"Aubert","year":"2020","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.1016\/j.sapharm.2021.05.007_bib11","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.therap.2018.10.006","article-title":"Pharmacoepidemiology in older people: purposes and future directions","volume":"74","author":"Laroche","year":"2019","journal-title":"Therapie"},{"issue":"20","key":"10.1016\/j.sapharm.2021.05.007_bib12","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.jacc.2019.03.467","article-title":"Deprescribing in older adults with cardiovascular disease","volume":"73","author":"Krishnaswami","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.sapharm.2021.05.007_bib13","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"4","key":"10.1016\/j.sapharm.2021.05.007_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0122246","article-title":"What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: a modified delphi process","volume":"10","author":"Farrell","year":"2015","journal-title":"PloS One"},{"issue":"5","key":"10.1016\/j.sapharm.2021.05.007_bib15","first-page":"339","article-title":"Deprescribing benzodiazepine receptor agonists: evidence-based clinical practice guideline","volume":"64","author":"Pottie","year":"2018","journal-title":"Can Fam Physician"},{"issue":"4","key":"10.1016\/j.sapharm.2021.05.007_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0174730","article-title":"Benzodiazepines, Z-drugs and the risk of hip fracture: a systematic review and meta-analysis","volume":"12","author":"Donnelly","year":"2017","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.sapharm.2021.05.007_bib17","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1001\/jama.2018.20578","article-title":"Association of aspirin use for primary prevention with cardiovascular events and bleeding events","volume":"321","author":"Zheng","year":"2019","journal-title":"J Am Med Assoc"},{"issue":"3","key":"10.1016\/j.sapharm.2021.05.007_bib18","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1093\/fampra\/cmz080","article-title":"A comparison of contemporary versus older studies of aspirin for primary prevention","volume":"37","author":"Moriarty","year":"2019","journal-title":"Fam Pract"},{"issue":"16","key":"10.1016\/j.sapharm.2021.05.007_bib19","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1803955","article-title":"Effect of aspirin on all-cause mortality in the healthy elderly","volume":"379","author":"McNeil","year":"2018","journal-title":"N Engl J Med"},{"issue":"65","key":"10.1016\/j.sapharm.2021.05.007_bib21","first-page":"481","article-title":"Update on acetylsalicylic acid for primary prevention of cardiovascular disease","volume":"21","author":"Truong","year":"2019","journal-title":"Can Med Assoc J"},{"issue":"13","key":"10.1016\/j.sapharm.2021.05.007_bib22","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1161\/CIRCULATIONAHA.117.028321","article-title":"Low-dose aspirin discontinuation and risk of cardiovascular events: a Swedish nationwide, population-based cohort study","volume":"136","author":"Sundstr\u00f6m","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.sapharm.2021.05.007_bib23","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"23","key":"10.1016\/j.sapharm.2021.05.007_bib24","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1001\/jama.2011.822","article-title":"Surveillance bias in outcomes reporting","volume":"305","author":"Haut","year":"2011","journal-title":"JAMA, J Am Med Assoc"},{"issue":"4","key":"10.1016\/j.sapharm.2021.05.007_bib25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"issue":"5","key":"10.1016\/j.sapharm.2021.05.007_bib26","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1007\/s11606-010-1609-1","article-title":"Healthy user and related biases in observational studies of preventive interventions: a primer for physicians","volume":"26","author":"Shrank","year":"2011","journal-title":"J Gen Intern Med"},{"issue":"7557","key":"10.1016\/j.sapharm.2021.05.007_bib27","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1136\/bmj.38875.675486.55","article-title":"A meta-analysis of the association between adherence to drug therapy and mortality","volume":"333","author":"Simpson","year":"2006","journal-title":"BMJ"},{"issue":"3","key":"10.1016\/j.sapharm.2021.05.007_bib28","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s40471-018-0155-y","article-title":"The importance and implications of comparator selection in pharmacoepidemiologic research","volume":"5","author":"D'Arcy","year":"2018","journal-title":"Curr Epidemiol Rep"},{"issue":"1","key":"10.1016\/j.sapharm.2021.05.007_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/pds.3334","article-title":"The incident user design in comparative effectiveness research","volume":"22","author":"Johnson","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.sapharm.2021.05.007_bib30","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/pds.4197","article-title":"Bias from depletion of susceptibles: the example of hormone replacement therapy and the risk of venous thromboembolism","volume":"26","author":"Renoux","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"10.1016\/j.sapharm.2021.05.007_bib31","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/aje\/kwr301","article-title":"Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins","volume":"175","author":"Danaei","year":"2012","journal-title":"Am J Epidemiol"},{"issue":"1","key":"10.1016\/j.sapharm.2021.05.007_bib32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.13063\/2327-9214.1234","article-title":"Comparative effectiveness research using observational data: active comparators to emulate target trials with inactive comparators","volume":"4","author":"Huitfeldt","year":"2016","journal-title":"eGEMs (Generat Evid Methods Improv Patient Outcomes)"},{"key":"10.1016\/j.sapharm.2021.05.007_bib33","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/pds.1584","article-title":"Replicated studies of two randomized trials of angiotensin- converting enzyme inhibitors: further empiric validation of the \u2018prior event rate ratio\u2019 to adjust for unmeasured confounding by indication","volume":"17","author":"Tannen","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.sapharm.2021.05.007_bib34","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1002\/pds.3724","article-title":"Performance of prior event rate ratio adjustment method in pharmacoepidemiology: a simulation study","volume":"24","author":"Uddin","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7691","key":"10.1016\/j.sapharm.2021.05.007_bib35","first-page":"395","article-title":"Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings","volume":"338","author":"Tannen","year":"2009","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.sapharm.2021.05.007_bib36","doi-asserted-by":"crossref","DOI":"10.1186\/s12882-019-1633-2","article-title":"Estimating the risk of acute kidney injury associated with use of diuretics and renin angiotensin aldosterone system inhibitors: a population based cohort study using the clinical practice research datalink","volume":"20","author":"Scott","year":"2019","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.sapharm.2021.05.007_bib37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jclinepi.2020.03.007","article-title":"Prior event rate ratio adjustment produced estimates consistent with randomized trial: a diabetes case study","volume":"122","author":"Rodgers","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.sapharm.2021.05.007_bib38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.sapharm.2021.05.007_bib39","doi-asserted-by":"crossref","DOI":"10.1007\/s11606-018-4795-x","article-title":"Patient characteristics and general practitioners' advice to stop statins in oldest-old patients: a survey study across 30 countries","author":"van der Ploeg","year":"2019","journal-title":"J Gen Intern Med"},{"issue":"7","key":"10.1016\/j.sapharm.2021.05.007_bib40","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time\u2010to\u2010event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"issue":"5","key":"10.1016\/j.sapharm.2021.05.007_bib41","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1111\/1475-6773.12182","article-title":"Methods for constructing and assessing propensity scores","volume":"49","author":"Garrido","year":"2014","journal-title":"Health Serv Res"},{"issue":"28","key":"10.1016\/j.sapharm.2021.05.007_bib42","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"issue":"23","key":"10.1016\/j.sapharm.2021.05.007_bib43","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting","volume":"323","author":"Thomas","year":"2020","journal-title":"J Am Med Assoc"},{"issue":"25","key":"10.1016\/j.sapharm.2021.05.007_bib44","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"10","key":"10.1016\/j.sapharm.2021.05.007_bib45","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1111\/jgs.14253","article-title":"Use and interpretation of propensity scores in aging research: a guide for clinical researchers","volume":"64","author":"Kim","year":"2016","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"10.1016\/j.sapharm.2021.05.007_bib46","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/ageing\/afw039","article-title":"Development and validation of an electronic frailty index using routine primary care electronic health record data","volume":"45","author":"Clegg","year":"2016","journal-title":"Age Ageing"},{"issue":"10132","key":"10.1016\/j.sapharm.2021.05.007_bib47","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","article-title":"Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study","volume":"391","author":"Gilbert","year":"2018","journal-title":"Lancet"},{"issue":"10165","key":"10.1016\/j.sapharm.2021.05.007_bib48","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1016\/S0140-6736(18)32424-3","article-title":"The challenges of using the hospital frailty risk score","volume":"392","author":"O'Caoimh","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.sapharm.2021.05.007_bib49","article-title":"Comment on: revascularization versus medical therapy in patients aged 80 Years and older with acute myocardial infarction","author":"Putot","year":"2020","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"10.1016\/j.sapharm.2021.05.007_bib50","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.sapharm.2021.05.007_bib51","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1136\/bmj.j4587","article-title":"Handling time varying confounding in observational research","volume":"359","author":"Mansournia","year":"2017","journal-title":"BMJ"},{"issue":"2","key":"10.1016\/j.sapharm.2021.05.007_bib52","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/pds.4372","article-title":"Methods for time-varying exposure related problems in pharmacoepidemiology: an overview","volume":"27","author":"Pazzagli","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"10.1016\/j.sapharm.2021.05.007_bib53","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/joim.12186","article-title":"Use of self-controlled designs in pharmacoepidemiology","volume":"275","author":"Hallas","year":"2014","journal-title":"J Intern Med"},{"issue":"13","key":"10.1016\/j.sapharm.2021.05.007_bib54","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1002\/sim.6128","article-title":"Instrumental variable methods for causal inference","volume":"33","author":"Baiocchi","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.sapharm.2021.05.007_bib55","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jclinepi.2017.04.011","article-title":"Montreal Accord on Patient-Reported Outcomes (PROs) use series \u2013 paper 8: patient-reported outcomes in electronic health records can inform clinical and policy decisions","volume":"89","author":"Ahmed","year":"2017","journal-title":"J Clin Epidemiol"},{"issue":"1","key":"10.1016\/j.sapharm.2021.05.007_bib56","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1186\/s13063-020-04259-5","article-title":"Discontinuing statins or not in the elderly? Study protocol for a randomized controlled trial","volume":"21","author":"Bonnet","year":"2020","journal-title":"Trials"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155174112100173X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155174112100173X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:25:18Z","timestamp":1761557118000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155174112100173X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S155174112100173X"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2021.05.007","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methods for evaluating the benefit and harms of deprescribing in observational research using routinely collected data","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2021.05.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}